Abpro Holdings, Inc. · OTC:ABPO

Abpro — Investor Presentation (February 2025)

27 slides from Abpro's investor presentation, Feb 21, 2025

  1. Slide 1: Corporate Presentation Q1 2025

    1 CORPORATE PRESENTATION Q1 2025

  2. Slide 2: Disclaimers: Forward-Looking Statements

    2 Disclaimers Forward - Looking Statements This presentation (“Presentation”) contains certain forward - looking statements within the meaning of the federal securities laws , including the products and services offered by Abpro Holdings, Inc. (“ Abpro ”) and the markets in which it operates and Abp

  3. Slide 3: Investment Highlights

    3 • Discovery: DiversImmune ® • Engineering: MultiMab TM Differentiated Platform Rapid discovery, design and optimization Robust Pipeline Novel, potentially best in class antibodies Validating Partnerships • Celltrion , Inc. (KRX: 068270) • Fully funding development of ABP - 102 • Up to $1.75B in to

  4. Slide 4: Experienced Leadership Team

    4 Ian Chan, MBA CEO, Co - founder Brown AB; Harvard MBA Eugene Chan, MD Chairman, Co - founder Harvard AB; Harvard MD Experienced Leadership Team Miles Suk Co - CEO, Board Member Michigan State U, BS Brown ScB, MMSc, MD Chief Medical Officer Robert Markelewicz, MD

  5. Slide 5: Experts on Scientific Advisory Board

    5 Robert Langer, PhD Ron Levy, MD Laurie Glimcher, MD George Tsokos, MD David H. Koch Institute Professor, MIT; Founder of Moderna, BIND, Momenta, AIR, others Professor and Chief, Division of Oncology, Stanford School of Medicine Former President and CEO, Dana - Farber Cancer Institute Professor of

  6. Slide 6: Pipeline with Next Generation Candidates

    6 $10.4 Billion 1 Anti - VEGF/ANG2 ABP - 201 DME/Wet AMD $12.1 Billion 2 Anti - HER2/CD3 ABP - 102 Breast, Gastric Cancer $12.9 Billion 3 Anti - GPC3/CD3 ABP - 110 Liver Cancer $13.11 Billion 4 Anti - CLAUDIN18.2/CD3 ABP - 150 Gastric Cancer INDICATION 1 Prescient and Strategic Intelligence, Wet Age

  7. Slide 7: Technology Platform

    TECHNOLOGY PLATFORM

  8. Slide 8: DiversImmune Discovery Platform

    8 Creates antibody therapies against a broad range of high value targets Key role in SAP program via platform for GSK SAP amyloid program in Phase 2 Validated by global pharma and research institutions Proven in 300+ campaigns during early years of development • Rapid Generation Swift production of

  9. Slide 9: MultiMab Antibody Engineering Platform and TetraBi Format

    9 • Bivalent binding to TAA 1 for potentially increased efficacy Enhancing efficacy and safety: fine - tuning antibody product formats for optimal results Anticipated Advantages of TetraBi Format: • Fc modification for reducing toxicity and increasing antibody half life • Flexible configuration for

  10. Slide 10: Lead Programs

    LEAD PROGRAMS • ABP - 102 • ABP - 201

  11. Slide 11: ABP-102: HER2/CD3 T-Cell Engager

    HER2/CD3 T - Cell Engager ABP - 102 Treatment for HER2+ Breast Cancer & Gastric Cancer

  12. Slide 12: ABP-102: Addressing Unmet Needs in HER2+ Cancers

    12 ABP - 102 Addressing Unmet Needs in HER2+ Cancers $12.1 billion Projected global HER2+ market size by 2030 1 Development Fully Funded By collaboration partner Celltrion • Current HER2 - directed therapies have demonstrated off target toxicity, drug resistance or limited potency, especially in the

  13. Slide 13: ABP-102: Strategic Partnership with Celltrion

    13 Leading biopharmaceutical company headquartered in Incheon, South Korea; KRX: 068270 Global Development & Commercialization Partnership Highlights • Celltrion funds all development costs, including preclinical and clinical studies • Abpro retains a 50% share of profits worldwide • Abpro to receiv

  14. Slide 14: ABP-102: Potent killing of HER2-high but not HER2-low cells

    14 ABP - 102: Potent killing of HER2 - high but not HER2 - low target cells in vitro HER2 - high HER2 - low Abpro internal data 14 (HER2 - null x CD3) HER2 affinity: HER2 x CD3 parental TetraBi > ABP - 102a > ABP - 102b > ABP - 102c

  15. Slide 15: ABP-102: Aiming to be Best-in-Class

    15 ABP - 102: Aiming to be Best - in - Class 3 1. ABP - 102(10.0) Binding affinity is not optimized (parental clone) 2. ABP - 102(10.5.1) Binding affinity is optimized 3. Source from : Celltrion Presentation in JPM Conference Jan 2025 ; Celltrion named “ABP - 102” as “CT - P72” in its presentation A

  16. Slide 16: ABP-201: VEGF/ANG2 Bispecific Antibody

    VEGF/ANG - 2 BISPECIFIC ANTIBODY ABP - 201 Treatment for Diabetic Macular Edema (“DME”) & Wet Age - related Macular Degeneration (”AMD”)

  17. Slide 17: ABP-201: Addressing Unmet Needs in Wet AMD/DME

    17 17 Potential Competitive Advantages: $10.4 billion Global Wet AMD market size projection in 2024 1 • Unlike Eylea and Lucentis, ABP - 201 seeks to inhibit both VEGF and ANG - 2 • Unlike Vabysmo, ABP - 201 has two binding sites for VEGF and ANG - 2, designed to more effectively trap each ligand •

  18. Slide 18: ABP-201 vs. Vabysmo

    18 ABP - 201: Anti - VEGF/ANG2 Target Indication: Wet AMD/DME Vabysmo ABP - 201 ABP - 201 vs. Vabysmo Key Characteristics Drive Differentiation Increased potential potency longer therapeutic duration Four high - affinity binding sites Larger molecular weight ABP - 201

  19. Slide 19: ABP-201: In Vivo Preclinical Models Have Positive Results

    19 ABP - 201: In Vivo Preclinical Models Have Positive Results Laser - induced neovascularization model in rats 2 Lesion volume Leakage score 1 PoweredResearch , Safety, Tolerability, and Pharmacokineti C Study Following Intravitreal ( IVT ) Delivery of a Novel Compound in Rabbit, April 27, 2021. 2

  20. Slide 20: ABP-201 Exhibits Favorable PK Compared with Vabysmo

    20 ABP - 201 Exhibits Favorable PK Compared with Vabysmo ABP - 201 PK in Rabbit vs. Faricimab PK in Cyno ABP - 201 0.2mg dose in Rabbit 2 Retina Vitreous Aqueous Serum Unit PK parameter 8.457 183.357 14.374 0.415 µg/ml C max 24 1 48 48 h T max 106 82 108 38 h t 1/2 1777 36922 2529 52 (ug*h)/ml AUC 0

  21. Slide 21: ABP-201: Current Status and Development Strategy

    21 ABP - 201 Current Status: • Investigation New Drug (IND) enabling studies underway • Co - development via a territorial partnership with Abpro Bio 1 • Abpro retains U.S. and European Union Five commercial rights Anticipated Development Plan • Q1 2026: File IND application and Initiate a Phase 1 t

  22. Slide 22: Additional T-Cell Engagers

    ADDITIONAL T - CELL ENGAGERS ABP - 150: Anti - Claudin 18.2/ CD3 against Gastric Cancer ABP - 110: Anti - GPC3/CD3 against Liver Cancer

  23. Slide 23: ABP-150: Anti-Claudin18.2/CD3 Key Characteristics

    23 • T - cell engager designed to fight cancer through co - targeting CD3 & Claudin 18.2 • Specific for Claudin 18.2, avoiding binding closely related isoform Claudin 18.1 expressed in the lung. • Showed potent killing in in vitro T cell - mediated killing assays in preclinical studies • Showed pote

  24. Slide 24: ABP-150: In Vivo Efficacy and Safety Profile

    24 ABP - 150: in vivo Efficacy and Safety Profile in Preclinical Models NUGC - 4 tumor cells mixed with human PBMCs and implanted subcutaneously in the same bolus into NSG mice. Potent in vivo efficacy in gastric cancer xenograft mouse model 1 ABP - 150 is well tolerated in a preclinical tox model 1

  25. Slide 25: ABP-110: Anti-GPC3/CD3 for Liver Cancer

    25 ABP - 110: Anti - GPC3/CD3 Target Indication: Hepatocellular Carcinoma - Liver Cancer • YP7 is originally in - licensed from NIH at early stage • 3BN9 x CD3 and 5V2A x CD3 are Abpro’s improved BsAbs HEP3B tumors + CD8 + T cells 2 HEPG2 tumors + CD8 + T cells 2 Designed to provide in - vitro T - c

  26. Slide 26: Anticipated Upcoming Milestones

    26 Anticipated Upcoming Milestone 2027 2026 2025 Timeline ABP - 102 ABP - 201 ABP - 150 ABP - 110 GLP Tox Data IND Filing Start Phase 1 GLP Tox Data IND Filing Start Phase 1 Start Phase 1 Start Phase 1 IND Filing IND Filing

  27. Slide 27: Thank you!

    Thank you! ABPRO HOLDINGS, INC. 68 Cummings Park, Woburn, MA 01801 https:// abpro.co / IR@abpro.co Mission: Developing antibody therapies to improve the lives of patients facing severe and life - threatening diseases

Abpro Holdings — Investor Presentation (February 2025) on 6ix